Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.

Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.

Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.

ISCK03 stops melanin production in human melanoma cells and lightens skin color in mice and guinea pigs.

JAK-inhibitors are effective for treating psoriasis and show promise for other skin diseases.

Tofacitinib may help regrow hair in alopecia areata patients.

JAK inhibitors can help treat alopecia areata but have risks and high costs.

Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.

Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.

Upadacitinib effectively treats pyoderma gangrenosum.

Mogamulizumab can cause hair loss, often linked to a better treatment response.

Abrocitinib may effectively treat Lichen Planopilaris.

Belimumab reduces disease activity, steroid use, and flares in lupus patients.

Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.

Anifrolumab helped some lupus patients reduce steroid use, but safety concerns remain.

Rizatriptan benzoate-loaded dissolving microneedles are effective and convenient for treating acute migraines.

JAK inhibitors can effectively reverse hair loss in people with alopecia areata.

Tofacitinib can help regrow hair in about 50% of people with moderate-severe alopecia areata.

Janus kinase inhibitors are promising drugs for treating autoimmune and inflammatory diseases.

A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.

JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.

Ruxolitinib can help regrow hair in severe alopecia areata.

CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.

Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.

The combination therapy was effective and well-tolerated, especially in young patients.

Medicaid coverage for alopecia areata treatments is inconsistent and often limited.

Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.

JAK inhibitors may help improve symptoms in adults with APECED.